1. Home
  2. OTEX vs RYTM Comparison

OTEX vs RYTM Comparison

Compare OTEX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Open Text Corporation

OTEX

Open Text Corporation

HOLD

Current Price

$23.01

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$98.30

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTEX
RYTM
Founded
1991
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.8B
IPO Year
1998
2017

Fundamental Metrics

Financial Performance
Metric
OTEX
RYTM
Price
$23.01
$98.30
Analyst Decision
Hold
Strong Buy
Analyst Count
10
14
Target Price
$36.10
$131.14
AVG Volume (30 Days)
1.1M
467.1K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
4.92%
N/A
EPS Growth
56.36
28.34
EPS
2.58
N/A
Revenue
$2,815,241,000.00
N/A
Revenue This Year
$2.82
$55.34
Revenue Next Year
$1.04
$86.06
P/E Ratio
$8.91
N/A
Revenue Growth
22.88
N/A
52 Week Low
$19.78
$74.50
52 Week High
$39.90
$122.20

Technical Indicators

Market Signals
Indicator
OTEX
RYTM
Relative Strength Index (RSI) 43.34 40.39
Support Level $21.83 $98.51
Resistance Level $23.71 $112.08
Average True Range (ATR) 0.63 3.31
MACD -0.08 -0.28
Stochastic Oscillator 23.12 32.21

Price Performance

Historical Comparison
OTEX
RYTM

About OTEX Open Text Corporation

Open Text Corp provides data management for enterprise AI, offering a secure data foundation and trusted context for credible AI outcomes across private, public, and sovereign cloud, managed cloud services, API, and on-premises environments. The Company also provides cybersecurity solutions to protect sensitive data, applications and systems across complex hybrid environments, including identity and access management, threat detection and response, data protection and application security. It serves private, public, and regulated sectors, including retail, financial services, government, manufacturing, healthcare, energy, and logistics, with clients. Geographically, it derives maximum revenue from the Americas.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: